Copenhagen, 2013-09-16 10:14 CEST (GLOBE NEWSWIRE) -- 

Report of insider transactions
No. 04/2013                   



Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S
(“Zealand”) shall announce transactions in the company’s shares and related
securities by executives and persons/companies closely related to them. 

In this regard, Zealand announces the following transaction:



Name:          David H. Solomon                     
----------------------------------------------------
Reason:        President and Chief Executive Officer
----------------------------------------------------
Issuer:        Zealand Pharma A/S                   
----------------------------------------------------
Type           Shares                               
----------------------------------------------------
ISIN code:     DK0060257814                         
----------------------------------------------------
Transaction:   Purchase                             
----------------------------------------------------
Trading date:  12 September 2013                    
----------------------------------------------------
Market:        NASDAQ OMX København A/S             
----------------------------------------------------
Amount:        10,000                               
----------------------------------------------------
Price:         DKK 64.00                            
----------------------------------------------------
Market value:  DKK 640,000.00                       
----------------------------------------------------



Hereafter, David H. Solomon owns 30,600 shares and 387,150 warrants in Zealand.

                                      ***





For further information, please contact:



David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com 





About Zealand PharmaZealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL)
(“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand
specializes in the discovery, optimization and development of novel peptide
drugs and has a broad and mature pipeline of drug candidates identified through
its own drug discovery activities. The company’s focus lies in the field of
cardio-metabolic diseases, diabetes and obesity in particular, and its lead
drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is
licensed to Sanofi for the treatment of Type 2 diabetes.  Lixisenatide
(marketed by Sanofi as Lyxumia®) is approved in Europe and Japan and under
regulatory review in a number of other countries globally. In the U.S., an NDA
is planned to be submitted in 2015, after completion of the ELIXA CV outcome
study. 



Zealand has a partnering strategy for the development and commercialization of
its products and in addition to the license agreement with Sanofi in Type 2
diabetes, the company has partnerships with Boehringer Ingelheim in
diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in
chemotherapy induced diarrhea and AbbVie in acute kidney injury. 



For further information: www.zealandpharma.com.

@ZealandPharma